ResMed Inc. stock price is expected to decrease after recent insider selling and institutional trimming.
Stock AI’s forecasts:
🔴 -15.0% short-term ⬇️
🔴 -4.9% long-term ⬇️
Stock AI’s (RMD) Forecast get (+14.6% Profit)
StockAI’s analysis delivers real-world results. On 15 March 2024, $RMD ($190.1), StockAI predicted a long-term 🟢 buy signal. It was accurate: 1 month later price increased to $217.8 (🟢14.6%). Buying RMD on this signal yielded a +14.6% profit 💰💰.
RMD-ResMed Inc. News
🟢 Director Karen Drexler sold 425 shares at $214.92, Commerce Bank lowered holdings by 15.0%, AGF Management Ltd. trimmed position by 2.9%, Great Lakes Advisors LLC decreased stake by 29.8%, Metis Global Partners LLC decreased holdings by 20.5%.
🔴 Director Witte Jan De sold 360 shares at $218.29, Los Angeles Capital Management LLC increased holdings by 647.0%, Jump Financial LLC reduced stake by 88.1%, Swiss National Bank cut holdings by 2.7%, Norges Bank purchased 1,360,110 shares, BI Asset Management Fondsmaeglerselskab A S raised position by 27.6%.
ResMed Inc. has seen a mix of positive and negative news in recent times, with company directors selling shares while institutional investors both decrease and increase their positions in the stock. The selling of shares by directors may signal lack of confidence in the company’s future performance, leading to a potential decrease in stock price. On the other hand, the increase in holdings by institutional investors could indicate a positive outlook on the company, potentially leading to a price increase. Overall, the stock may experience some volatility in the short term due to these conflicting signals, but in the long term, the negative impact of director sales may outweigh the positive impact of institutional purchases, resulting in a decrease in stock price. Investors should closely monitor these developments to make informed decisions about their investments in ResMed Inc.
RMD-ResMed Inc. Analyst Ratings
In recent analyst ratings for ResMed Inc. (NYSE:RMD) stock, there have been notable changes:
📈 Piper Sandler analysts upgraded their rating on ResMed Inc. stock from Neutral to Overweight and set a target price of $230.
📉 Citigroup analysts downgraded their rating on ResMed Inc. stock from Buy to Hold and lowered the target price from $220 to $200.
📈 Goldman Sachs analysts raised their rating on ResMed Inc. stock from Sell to Neutral and increased the target price from $190 to $210.
Sources:
1. Piper Sandler
2. Citigroup
3. Goldman Sachs
Disclaimer
Investors may consider the AI predictions and news summaries as one factor in their investment decisions alongside their own research and risk tolerance.
Ready to analyze your own portfolio?
Get the same AI-powered insights for any stock you choose. It's easy!
